We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Pushes Back Reviews for More JAK Inhibitors
The FDA has moved to delay more reviews of oral Janus Kinase (JAK) inhibitors after recently pushing back its review timeframe for AbbVie’s Rinvoq (upadacitinib), postponing its decisions on separate submissions filed by Pfizer and Eli Lilly/Incyte by three months.